Partnerships & Alliances
Filter News
Found 47,471 articles
-
Remote Medical International Partners With 1health.io to Provide COVID-19 Saliva Tests That Can Be Administered From Anywhere
10/23/2020
Remote Medical International, the company providing workplace health and safety services for Fortune 100 corporations, today announced it has partnered with 1health.io, the leading testing as a service (TaaS) company, to deliver saliva-based COVID-19 tests to its customers working in isolated work sites across the country
-
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
10/23/2020
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
-
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample. They published the research today in The Lancet eClinicalMedicine.
-
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
-
Trans-Hit Biomarkers Announces Today a Partnership With Nexelis, Supporting Sample Procurement Activities for a Number of Strategic Projects Including COVID-19 Vaccines and Immuno-oncology Development Initiatives.
10/22/2020
Trans-Hit Biomarkers Inc. (THB) is pleased to announce today the signing of a partnership agreement with Laboratoires Nexelis Canada Inc. (Nexelis) to support prophylactic and therapeutic vaccine development programs sponsored by global pharmaceutical companies, innovative biotechnology companies, and prestigious governmental and non-governmental organizations including Bill and Melinda Gates Foundation (BMGF) and Coalition for Epidemic Preparedness Innovations (CEPI).
-
Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
10/22/2020
Avalon GloboCare Corp. (AVCO ) , a clinical-stage, global developer of cell-based technologies and therapeutics and Adial Pharmaceuticals, Inc. today announced formation of a strategic collaboration for global distribution of the Assure/Fastep® COVID-19 IgG/IgM Rapid Test device and the Assure/EcoStep® COVID-19 IgG/IgM Rapid Test device
-
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep(R) Point-of-Care Covid-19 Antibody Tests
10/22/2020
Todos Medical (TOMDF) an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimers disease, along with Adial Pharmaceuticals, Inc.
-
Contakt World Enters 3-Year Strategic Collaboration with Satcher Health Leadership Institute at Morehouse School of Medicine
10/22/2020
Partnership to Improve Health Equity, Reduce Health Disparities, and Improve Community Health Amid COVID-19 Pandemic
-
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
10/22/2020
Todos Medical (OTCQB:TOMDF) (“Todos”) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, along with Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the developmen
-
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
10/22/2020
Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases,
-
Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine
10/22/2020
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute
-
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
10/22/2020
Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In
-
Aesthetic Medical International Holdings Group Limited Enters into Strategic Cooperation Agreement with Chengdu Meb Network Technology Co., Ltd.
10/22/2020
Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces it has entered into a strategic cooperation agreement (the “Agreement”) with Chengdu Meb Network Technology Co., Ltd. (“Meb”),
-
IAVI, Merck KGaA, Darmstadt, Germany, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
10/22/2020
Today, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research
-
Vidence and NTT DATA Announce Partnership to Deliver Predictive Analytics in Oncology
10/22/2020
Vidence, an oncology informatics company, and NTT DATA Services, a global digital business and IT services leader, today announced a relationship to build advanced artificial intelligence (AI) and machine learning (ML) algorithms to predict patient outcomes, enhance decision-making, and drive clinical trials to advance cancer research and treatment
-
Kedrion's Partner, Kamada Ltd, Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy
10/22/2020
The Israeli health authorities have signed a supply agreement for the investigational COVID-19 plasma-derived Immunoglobulin (IgG), to be supplied by Kamada Ltd., a biopharmaceutical company which is the partner of Kedrion Biopharma of Italy in the development of the new anti-COVID-19 therapy.
-
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
10/22/2020
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction Bo Cumbo, most recently Sarepta’s Chief Commercial Officer and Executive Vice President, appointed Chief Executive Officer and President of AavantiBio Co-founded by pioneering gene therapy researchers Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D.,
-
Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19
10/22/2020
Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
-
Cohere Health Announces Partnership with Humana to Modernize Prior Authorization and Improve Physician and Member Experience
10/22/2020
CohereNext® Platform, co-designed with physicians, enables health plans and physicians to align on patient care journeys, driving improved quality and safety
-
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland
10/21/2020
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi ® and Submits Market Authorization Application in Switzerland FREIENBACH, Switzerland--( BUSINESS WIRE )-- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a